An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Distribution, Metabolism and Excretion of [14C]-STX-478 Following Single-Dose Oral Administration

The main purpose of this study is to conduct blood tests to measure how much STX-478 is in the bloodstream and how the body handles and eliminates it in healthy participants. This study will involve a single dose of 14C radiolabeled STX-478. This means that a radioactive tracer substance, C14, will be incorporated into the study drug STX-478 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of STX-478.

开始日期2025-03-20

申办/合作机构

Scorpion Therapeutics, Inc.

NCT05768139

/ Recruiting临床1/2期

First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations.
Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with endocrine therapy (aromatase inhibitors, fulvestrant or imlunestrant) and a CDK4/6 Inhibitor (either Ribociclib, Palbociclib or Abemaciclib) in participants with HR+ breast cancer.
Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.

开始日期2023-04-17

申办/合作机构

Scorpion Therapeutics, Inc.

100 项与 Tersolisib 相关的临床结果

登录后查看更多信息

100 项与 Tersolisib 相关的转化医学

登录后查看更多信息

100 项与 Tersolisib 相关的专利（医药）

登录后查看更多信息

项与 Tersolisib 相关的文献（医药）

2025-08-19·Annual Review of Pharmacology and Toxicology

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα

Review

作者: Liu, Xiao ; Chen, Yan ; Feng, Wenbo ; Zhou, Qingtong ; Chen, Yanyan ; Han, Wei ; Wang, Ming-Wei

Phosphoinositide 3-kinase alpha (PI3Kα) is a pivotal regulator of cell growth, proliferation, and survival. Dysregulation of the PI3K/AKT/mTOR pathway, driven predominantly by PIK3CA mutations (e.g., H1047R, E542K, and E545K), is a hallmark of many cancers. Advances in structural, biochemical, and computational studies have elucidated mutation-specific conformational changes of PI3Kα. While early pan- and isoform-selective PI3K inhibitors (alpelisib) show clinical utility, their intrinsic toxicity and resistance to treatment persist. Recent breakthroughs include the emergence of allosteric inhibitors (RLY-2608 and STX-478) that exploit mutation-induced cryptic pockets to achieve mutant selectivity as well as covalent inhibitors and degraders (inavolisib) that enhance specificity, aiming at decoupling antitumor activity from metabolic dysfunction. This review synthesizes current progress in PI3Kα inhibitor development, emphasizing structural characteristics, clinical challenges, and emerging strategies. Addressing challenges to increase mutant selectivity, exploring conformational modulation, uncovering new mechanisms of action, and implementing personalized therapies are key future directions for PI3Kα-targeted drug discovery.

2025-08-10·BRITISH JOURNAL OF CANCER

Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models

Article

作者: Cantley, Lewis C ; Mukherjee, Siddhartha ; Goncalves, Marcus D ; Maddocks, Oliver D K ; Tyrakis, Petros A ; Kampjut, Domen ; Lindström, H Jonathan G ; Hopkins, Benjamin D ; Chirnomas, Deborah ; Steele, Georgina F

Abstract:

Background:

While PI3K/AKT/mTOR signalling plays a critical role in cancer, targeting this pathway with single node inhibitors has limited efficacy due to several known factors such as pathway feedback reactivation, co-occurring pathway mutations, and systemic glucose dysregulation leading to hyperinsulinemia. While multi-node inhibition approaches have shown promising clinical efficacy, they require further mechanistic characterisation.

Methods:

Using models of endometrial and breast cancer, we evaluated the efficacy of a multi-node PI3K/AKT/mTOR pathway inhibitor approach utilising the dual mTORC1/mTORC2 inhibitor sapanisertib, PI3Kα inhibitor serabelisib and an insulin-supressing diet. Pathway signalling inhibition versus a range of single-node inhibitors was measured via S6, AKT and 4E-BP1 phosphorylation.

Results:

The serabelisib-sapanisertib combination more effectively suppressed PI3K/AKT/mTOR pathway signalling, particularly 4E-BP1, than single-node inhibitors, including alpelisib, capivasertib, inavolisib, everolimus and mutant-specific PI3K inhibitors RLY-2608 and STX-478. Serabelisib plus sapanisertib combined effectively with a range of other therapeutics, such as chemotherapies, hormone targeted therapies and CDK4/6 inhibitors. In xenograft models, sapanisertib, serabelisib plus paclitaxel/insulin supressing diet achieved complete inhibition of tumour growth/tumour regression.

Conclusion:

Multi-node PI3K/AKT/mTOR pathway inhibition with serabelisib, sapanisertib and ISD is highly effective in preclinical models of endometrial and breast cancer, supporting continued clinical development in these and other solid tumours.

2024-12-01·Computational and Structural Biotechnology Journal

Free energy landscape of the PI3Kα C-terminal activation

Article

作者: Burke, John E ; Papadourakis, Michail ; Cournia, Zoe ; Kotzampasi, Danai Maria ; Burke, John E.

The gene PIK3CA, encoding the catalytic subunit p110α of PI3Kα, is the second most frequently mutated gene in cancer, with the highest frequency oncogenic mutants occurring in the C-terminus of the kinase domain. The C-terminus has a dual function in regulating the kinase, playing a putative auto-inhibitory role for kinase activity and being absolutely essential for binding to the cell membrane. However, the molecular mechanisms by which these C-terminal oncogenic mutations cause PI3Kα overactivation remain unclear. To understand how a spectrum of C-terminal mutations of PI3Kα alter kinase activity compared to the WT, we perform unbiased and biased Molecular Dynamics simulations of several C-terminal mutants and report the free energy landscapes for the C-terminal "closed-to-open" transition in the WT, H1047R, G1049R, M1043L and N1068KLKR mutants. Results are consistent with HDX-MS experimental data and provide a molecular explanation why H1047R and G1049R reorient the C-terminus with a different mechanism compared to the WT and M1043L and N1068KLKR mutants. Moreover, we show that in the H1047R mutant, the cavity, where the allosteric ligands STX-478 and RLY-2608 bind, is more accessible contrary to the WT. This study provides insights into the molecular mechanisms underlying activation of oncogenic PI3Kα by C-terminal mutations and represents a valuable resource for continued efforts in the development of mutant selective inhibitors as therapeutics.

项与 Tersolisib 相关的新闻（医药）

2025-07-01

·药明康德

22家创新药公司完成新一轮融资！

▎药明康德根据药明康德数据库统计，截至2025年6月30日，2025年6月全球生物医药领域共计完成146起融资活动，累计公开披露的融资总额超过了43亿美元。其中，有22家专注于开发创新疗法的公司完成的单笔融资额突破了5000万美元大关。这些公司不仅涵盖了传统的小分子药物研发，还包括了多种创新的新分子疗法领域。在接下来的内容中，我们将依据公开资料为读者介绍其中3家获得大额融资的创新药开发公司，探讨它们所开发的创新疗法以及这些疗法未来可能带来的患者福祉。Antares Therapeutics：小分子药物研发公司6月10日，Antares Therapeutics宣布正式成立并完成1.77亿美元A轮融资。本轮融资由Omega Funds、Atlas Venture、Lightspeed Venture Partners、BVF Partners和Cormorant Asset Management共同领投，Vinyanshu Ventures、Abingworth、Invus、Tenmile、Vida Ventures及Willett Advisors等机构跟投。Antares是Scorpion Therapeutics的分拆公司，后者曾于2025年3月将其突变选择性PI3Kα抑制剂项目STX-478以最高25亿美元出售给礼来公司（Eli Lilly and Company）。Scorpion在成立的五年间累计融资4.2亿美元，与多家药企达成合作，并成功推进6个开发候选药物，其中3个已进入临床阶段。作为一家专注于"难以成药"靶点开发的生物技术公司，Antares致力于突破转录因子等传统小分子难以干预的领域。该公司计划通过整合计算化学与实验生物学技术，推进涵盖精准肿瘤学及其他治疗领域的小分子研发管线。其首个候选药物预计将于2026年进入临床阶段，且目前还有多个项目处于临床前开发阶段。此外，Antares已与阿斯利康（AstraZeneca）、Pierre Fabre及Moma Therapeutics等企业达成合作，共同推进小分子药物开发。Adam Friedman博士目前担任Antares的首席执行官（CEO），在执掌Antares之前，他曾担任Scorpion Therapeutics的CEO。作为一名成就卓著的医师、科学家和生命科学领域连续创业者，他在肿瘤治疗研发领域拥有丰富的经验。其职业生涯还包括创立肿瘤靶点发现平台公司Vivid Biosciences并担任CEO，以及出任Raze Therapeutics业务发展总监和Atlas Venture驻场创业家等职。SpliceBio：基因疗法研发公司6月11日，SpliceBio宣布完成1.35亿美元的B轮融资，该融资由新投资者EQT Life Sciences和Sanofi Ventures共同领投，罗氏风投基金（Roche Venture Fund）参与投资，现有投资方全部跟投，包括：New Enterprise Associates、UCB Ventures、Ysios Capital、Gilde Healthcare、Novartis Venture Fund和Asabys Partners。SpliceBio此次募集的资金将主要用于推进其主打基因治疗候选药物SB-007的临床开发进程，包括正在进行中的1/2期ASTRA临床试验和POLARIS研究。根据该公司新闻稿，SB-007是首个经美国FDA批准进入临床开发用于治疗斯塔加特病（Stargardt disease）的双腺病毒（AAV）基因疗法。值得一提的是，除了美国FDA之外，SB-007还成功取得了英国药品和健康产品管理局（MHRA）的临床开发许可。 SpliceBio是一家临床阶段基因治疗公司，其核心技术优势在于开创性地运用蛋白质剪接技术，治疗由大型基因中的突变引发的疾病。该公司正通过突破AAV载体的根本性技术瓶颈——即无法递送超过4.7千碱基包装容量的大型基因，从而重新界定并拓展基因疗法的疾病治疗范畴。SpliceBio的独特蛋白质剪接平台，依托一类专有的工程化蛋白质——内含肽（inteins）构建。具体技术路径为：将目标基因拆分为两个（或多个）转基因片段，通过双AAV载体进行递送。当转基因进入细胞后，其携带的DNA会转录为信使RNA，进而翻译成蛋白质片段；此时，该公司设计的工程化内含肽会发挥作用，将这些蛋白质片段精准组装成具有完整功能的全长治疗性蛋白，从而实现疾病治疗的目的。Miquel Vila-Perelló博士是SpliceBio的联合创始人兼首席执行官，自2014年公司成立以来一直领导其战略发展。SpliceBio从早期概念验证阶段快速成长为一家具有全球影响力的临床阶段生物科技企业，成功推进了多个创新治疗项目的开发。Vila-Perelló博士在蛋白质工程与治疗应用领域深耕20余年，致力于推动前沿生物技术的转化研究，其科学洞察力和领导力为SpliceBio的技术平台构建和管线发展奠定了坚实基础。Draig Therapeutics：神经疾病药物研发公司6月18日，Draig Therapeutics宣布结束隐匿模式正式亮相。在过去九个月内，该公司已累计融资1.4亿美元（1.07亿英镑）。本轮超额认购的A轮融资由Access Biotechnology领投，Canaan Partners、SR One、Sanofi Ventures、Schroders Capital以及联合创立该公司的种子轮投资方SV Health Investors和ICG共同参投。新获资金将助力Draig公司在2025年将其主要候选药物DT-101（一种下一代AMPA受体正性异位调节剂）推进到治疗重度抑郁症的2期试验阶段。该药物旨在实现对AMPA受体的有效调节的同时，确保良好的安全性。值得关注的是，包含60余名受试者的1a期临床研究数据显示，DT-101展现出优异的耐受性；同时，通过脑磁图技术明确证实其靶点结合作用。相关研究结果即将在科学会议上公布。Ruth McKernan博士作为Draig Therapeutics的创始人兼执行主席，在医药领域拥有20多年深厚积淀。她曾主导默沙东（MSD）神经科学研究中心（ Neuroscience Research Centre）与辉瑞（Pfizer）药物发现技术中心（Discovery Technology Centre）等机构的战略运营，在离子通道与再生医学领域建树颇丰，已发表120余篇学术论文。McKernan博士通过创立Draig等多家生物技术公司，已成功推动多项科研成果落地。McKernan博士现任英国阿尔茨海默病研究基金会（Alzheimer's Research UK）理事等多项重要职务，并凭借其出色的科学传播能力成为屡获殊荣的科学作家，在学术界与产业界均发挥着重要的跨领域影响力。限于篇幅，本文无法对所有公司进行介绍，如需获取完整信息，请参阅《2025年6月全球5000万美元以上融资事件盘点》（详见下图）。参考资料：各公司官网免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

基因疗法临床研究

2025-06-16

·医药观澜

7家创新药公司完成新一轮融资！

根据公开信息，上周（6月9日~6月15日），全球范围内有至少7家致力于创新药研发的新锐公司宣布完成新一轮融资。通过梳理，这些获得资本青睐的新锐公司正在开发的产品包括放射性药物、多肽、基因治疗药物、小分子药物等等，聚焦的疾病领域涵盖了癌症、抑郁症等神经系统疾病、阻塞性睡眠呼吸暂停（OSA）等。景嘉航融资轮次：天使轮融资金额：数千万元6月13日，杭州景嘉航生物医药科技有限公司（AB-RayBio Therapeutics，简称“景嘉航”）完成数千万元人民币的天使轮融资。本轮融资由杭实资管领投，正景资本和滨江伍零伍零跟投，所募资金将主要用于公司现有管线的临床前和早期临床开发。景嘉航成立于2024年5月，是一家处于临床研究阶段的创新药公司，聚焦新型的靶向放射性药物的研发。该公司专注攻克癌症等重大疾病，旨在为临床提供精准诊断与靶向治疗的诊疗一体化解决方案。景嘉航目前拥有8条在研管线，其中JJH002管线数据优异，已经处于IIT阶段和IND申请准备阶段。Enterome融资轮次：未披露融资金额：1900万美元6月12日，Enterome公司宣布通过新一轮私募融资筹集1900万美元，以推进其治疗惰性非霍奇金淋巴瘤（iNHL）的主导临床项目EO2463 OncoMimics免疫疗法。新资金将用于扩大并完成正在进行的EO2463 1/2期SIDNEY临床试验，并为该候选药物的注册试验做准备。EO2463是一种创新型即用型免疫治疗候选药物，由4种模拟B细胞肿瘤相关抗原CD20、CD22，CD37和CD268（BAFF受体）的多肽以及辅助性的UCP2肽组成，能够激活抗肿瘤免疫反应，清除癌变B细胞。Enterome公司的OncoMimics管线包含三个临床阶段候选药物：治疗惰性非霍奇金淋巴瘤的EO2463；治疗三线结直肠癌的EO4010；治疗胶质母细胞瘤和肾上腺肿瘤的EO2401。这些候选药物均显示出积极的早期临床疗效及安全性和耐受性。因诺惟康融资轮次：A+轮融资金额：数千万元6月12日，北京因诺惟康医药科技有限公司（简称“因诺惟康”，InnoVec Biotherapeutics）宣布完成数千万元的A+轮融资，本轮投资由天创资本领投，新投资人及老股东跟投。所募集的资金将主要用于公司产品管线的临床验证和推进以及基因递送平台的创新。因诺惟康是一家以载体创新为驱动的临床阶段基因治疗公司，致力于开发适用于人体的基因治疗递送工具，使基因治疗能够广泛应用到罕见疾病和常见疾病当中。因诺惟康聚焦眼科，神经和肌肉等多个疾病领域，多个创新产品已经进入IIT和IND阶段。Elkedonia融资轮次：种子轮融资金额：1125万欧元6月11日，Elkedonia宣布超额完成1125万欧元种子轮融资。本轮融资由Kurma Partners、WE Life Sciences和French Tech Seed基金共同领投，Argobio、Angelini Ventures、CARMA Fund、Capital Grand Est及Sambrinvest参与投资。Elkedonia公司聚焦新型细胞内靶点Elk1——该蛋白在奖赏脑回路和神经可塑性中起关键作用，而这些机制在抑郁症、创伤后应激障碍（PTSD）和成瘾等疾病中发生异常。Elkedonia正在开发一种神经可塑性药物，旨在恢复神经可塑性且不产生致幻剂或氯胺酮衍生物的副作用。临床前和临床研究证据表明，抑制Elk1是实现抑郁症快速治疗的有效途径，且无镇静、依赖、致幻等现有抗抑郁疗法常见副作用。Antares Therapeutics融资轮次：A轮融资金额：1.77亿美元6月10日，Antares Therapeutics宣布启动1.77亿美元A轮融资。本轮融资由Omega Funds、Atlas Venture、Lightspeed Venture Partners、BVF Partners和Cormorant Asset Management共同领投，Vinyanshu Ventures、Abingworth、Invus、Tenmile、Vida Ventures及Willett Advisors参与投资。Antares是Scorpion Therapeutics的分拆公司，后者于2025年3月将其突变选择性PI3Kα抑制剂项目STX-478以最高25亿美元总对价授权给礼来公司（Eli Lilly and Company），且五年间累计融资4.2亿美元，与多家药企达成合作，并产生6个开发候选药物，其中3个已进入临床测试。Antares正在推进包括精准肿瘤学和其他治疗领域在内的小分子资产管线，该公司还宣布与皮尔法伯（Pierre Fabre ）达成协议，后者获得两个临床阶段高选择性新一代突变EGFR抑制剂（用于治疗非小细胞肺癌）的全球权益。32 Biosciences融资轮次：未披露融资金额：600万美元6月10日，32 Biosciences宣布获得600万美元融资，用于支持其主导资产的持续开发。该公司的治疗性创新产品是一种非抗生素类抗菌剂，通过抑制毒力基因表达、增强肠道黏膜屏障及促进有益菌生长来预防肠道源性细菌感染。该疗法有望在不导致抗生素耐药性的前提下显著降低感染率及感染相关死亡率。Mosanna Therapeutics融资轮次：A轮融资金额：8000万美元6月9日，临床阶段生物技术公司Mosanna Therapeutics宣布完成8000万美元A轮融资。该公司正在开发一种夜间使用的便捷鼻喷剂，旨在通过恢复人体自然气道调控功能，治疗阻塞性睡眠呼吸暂停（OSA）。本轮融资由EQT生命科学和Pivotal bioVenture Partners领投，Forbion、Broadview Ventures及Norwest共同领投，创始投资者Forty51 Ventures以及Supermoon Capital、High-Tech Gründerfonds（HTGF）跟投。MOS118的作用机制是通过靶向维持气道通畅的上呼吸道肌肉，恢复患者夜间减弱的自然气道反射功能。新闻稿介绍，Mosanna的突破性在于将睡眠呼吸暂停视为神经肌肉功能障碍而非单纯机械问题，MOS118有望成为首个通过鼻喷形式恢复人体自然气道反射的疗法，有望显著提升长期缺乏有效治疗手段的患者依从性和治疗效果。期待在资本的助力下，更多前沿疗法和技术能够更快惠及患者。参考资料：[1]各公司官网及公开资料版权说明：本文欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权或其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床申请免疫疗法基因疗法放射疗法临床1期

2025-06-11

·Pharmaceutical Technology

Antares Therapeutics gains $177m for cancer medicines development

The company intends to introduce its inaugural product candidate into clinical trials by 2026. Credit: Komsan Loonprom/Shutterstock. Antares Therapeutics has secured $177m in a Series A financing round for the development of precision medicines to treat cancer and other serious diseases. The company is progressing several programmes, intending to introduce its inaugural product candidate into clinical trials by 2026. The round was co-led by Atlas Venture, Omega Funds, Lightspeed Venture Partners, BVF Partners and Cormorant Asset Management. Additional support came from Abingworth, Invus, Tenmile, Vida Ventures, Vinyanshu Ventures and Willett Advisors. Antares Therapeutics CEO Adam Friedman stated: “We are building from a strong foundation with a team of experts who are experienced in making new medicines, as well as proprietary drug discovery capabilities and a robust preclinical pipeline fuelled by discoveries in drugging previously inaccessible targets. “We are committed to leveraging our expertise to address well-validated, first-in-class targets across oncology and other serious diseases, and to continuing to execute a fast-to-clinic strategy to bring medicines to patients in need.” GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The newly established company is a spin-out from Scorpion Therapeutics, which sold its STX-478 programme to Eli Lilly in March 2025 for $2.5bn. Founded in 2020, Scorpion raised $420m in the next five years while partnering with several pharmaceutical firms and producing six development candidates, three of which are now undergoing clinical trials. Under the guidance of Scorpion’s former executive leadership team, Antares aims to progress small-molecule assets developed at Scorpion within precision oncology, among other areas. Pierre Fabre Laboratories has acquired global rights to two clinical-stage mutant epidermal growth factor receptor inhibitors from Scorpion for non-small cell lung cancer treatment. With this deal, Pierre Fabre will oversee their continued clinical development and global commercialisation efforts while Antares stands to gain regulatory milestones as well as tiered royalties. Pharmaceutical Technology Excellence Awards - Have you nominated? Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact . This is your chance to showcase your achievements, highlight industry advancements , and gain global recognition . Don't miss the opportunity to be honoured among the best - submit your nomination today! Nominate Now

100 项与 Tersolisib 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床2期	美国	Scorpion Therapeutics, Inc.	2023-04-17
晚期恶性实体瘤	临床2期	法国	Scorpion Therapeutics, Inc.	2023-04-17
晚期恶性实体瘤	临床2期	意大利	Scorpion Therapeutics, Inc.	2023-04-17
晚期恶性实体瘤	临床2期	西班牙	Scorpion Therapeutics, Inc.	2023-04-17
HR阳性乳腺癌	临床2期	美国	Scorpion Therapeutics, Inc.	2023-04-17
HR阳性乳腺癌	临床2期	法国	Scorpion Therapeutics, Inc.	2023-04-17
HR阳性乳腺癌	临床2期	意大利	Scorpion Therapeutics, Inc.	2023-04-17
HR阳性乳腺癌	临床2期	西班牙	Scorpion Therapeutics, Inc.	2023-04-17
HR阳性/HER2阴性乳腺癌	临床2期	美国	Scorpion Therapeutics, Inc.	2023-04-17
HR阳性/HER2阴性乳腺癌	临床2期	法国	Scorpion Therapeutics, Inc.	2023-04-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05768139 (ESMO2024) 人工标引	临床1/2期	晚期恶性实体瘤 PI3Kαm	61	STX-478	願構糧淵網鑰獵構鬱醖(鏇範鬱衊積糧夢鹽選築) = 選範遞鏇夢鏇鏇願構簾獵憲網選鑰廠艱糧鹹淵 (鏇衊壓淵繭憲獵網齋範 ) 更多	积极	2024-09-15
				STX-478 (HR+/HER2- BC)	顧廠糧選範顧鹹淵淵遞(簾築選顧範糧遞廠鬱簾) = 糧觸鹽遞鑰範選糧壓顧醖鑰夢齋餘築觸廠顧簾 (齋繭齋壓襯餘餘醖餘鏇 )